<DOC>
	<DOCNO>NCT00342303</DOCNO>
	<brief_summary>We test follow hypothesis : 1 . The activity desaturating/elongating enzyme assess vivo conversion deuterated a-linolenic linoleic acid DHA AA , respectively , related duration gestation postnatal age . 2 . Dietary w-3 w-6 LCPUFAs human milk DHA AA supplement formula inhibit desaturation/elongation deuterated a-linolenic linoleic acid demonstrate vivo inhibition metabolic pathway respective product . Present evidence suggest parent essential fatty acid ( EFA ) , linoleic acid ( 18:2 w-6 ) a-linolenic acid ( 18:3 w-3 ) insufficient fully satisfy EFA nutrition early life human . A possible need long chain ( LC , longer 18 C chain length ) EFAs human suggest accretion rate elongate desaturated product develop fetus ; alter plasma red cell fatty acid pattern , abnormal visual function observe infant receive solely parent EFAs ; relatively high concentration LC EFAs human milk . Most milk formula , compare human milk , low oleic acid , high linoleic , little a-linolenic acid virtually LC w-3 w-6 polyunsaturated FA ( LC PUFA ) . This study evaluate capacity human infant form w-3 w-6 LCPUFAs parent EFAs affect developmental stage dietary EFA supply . The precursor label deuterium product analyze gas chromatography / mass spectrometry GC/MS . The main product desaturation / elongation pathway docosahexaenoic ( DHA ) arachidonic ( AA ) acids w-3 w-6 series , respectively . Infants feed human milk formula without supplemental LCPUFAs part study evaluate effect EFAs CNS functional development . Infants include study effect developmental stage EFA desaturation/elongation 2-5 day age ( fat administer enterally parenterally ) 28 , 32 , 36 40 week gestation . In addition , infant bear 28 40 week gestation study 2 6 week postnatally dietary fat provide least 7 day energy intake sufficient assure growth . To evaluate effect dietary EFA DHA AA formation ass elongation/ desaturation infant receive 3 diet : human milk ( contain w-3 w-6 LCPUFAs ) ; cow milk base formula provide 18:2 w-6 18:3 w-3 LCPUFAs ; formula supplement added LCPUFAs ( DHA AA ) . This study provide new information effect developmental stage w-3 w-6 LCPUFA supply determine activity EFA elongation/desaturation human . This knowledge may help improve early neonatal nutritional practice assure meet EFA need develop CNS .</brief_summary>
	<brief_title>Activity Essential Fatty Acid Elongation/Desaturation Pathway During Early Life Human Infants , In Vivo</brief_title>
	<detailed_description>We test follow hypothesis : 1 . The activity desaturating/elongating enzyme assess vivo conversion deuterated a-linolenic linoleic acid DHA AA , respectively , related duration gestation postnatal age . 2 . Dietary w-3 w-6 LCPUFAs human milk DHA AA supplement formula inhibit desaturation/elongation deuterated a-linolenic linoleic acid demonstrate vivo inhibition metabolic pathway respective product . Present evidence suggest parent essential fatty acid ( EFA ) , linoleic acid ( 18:2 w-6 ) a-linolenic acid ( 18:3 w-3 ) insufficient fully satisfy EFA nutrition early life human . A possible need long chain ( LC , longer 18 C chain length ) EFAs human suggest accretion rate elongate desaturated product develop fetus ; alter plasma red cell fatty acid pattern , abnormal visual function observe infant receive solely parent EFAs ; relatively high concentration LC EFAs human milk . Most milk formula , compare human milk , low oleic acid , high linoleic , little a-linolenic acid virtually LC w-3 w-6 polyunsaturated FA ( LC PUFA ) . This study evaluate capacity human infant form w-3 w-6 LCPUFAs parent EFAs affect developmental stage dietary EFA supply . The precursor label deuterium product analyze gas chromatography / mass spectrometry GC/MS . The main product desaturation / elongation pathway docosahexaenoic ( DHA ) arachidonic ( AA ) acids w-3 w-6 series , respectively . Infants feed human milk formula without supplemental LCPUFAs part study evaluate effect EFAs CNS functional development . Infants include study effect developmental stage EFA desaturation/elongation 2-5 day age ( fat administer enterally parenterally ) 28 , 32 , 36 40 week gestation . In addition , infant bear 28 40 week gestation study 2 6 week postnatally dietary fat provide least 7 day energy intake sufficient assure growth . To evaluate effect dietary EFA DHA AA formation ass elongation/ desaturation infant receive 3 diet : human milk ( contain w-3 w-6 LCPUFAs ) ; cow milk base formula provide 18:2 w-6 18:3 w-3 LCPUFAs ; formula supplement added LCPUFAs ( DHA AA ) . Also , relative efficiency conversion 18-C precursor compare 20-C precursor respect metabolic endpoint . This study provide new information effect developmental stage w-3 w-6 LCPUFA supply determine activity EFA elongation/desaturation human . This knowledge may help improve early neonatal nutritional practice assure meet EFA need develop CNS .</detailed_description>
	<criteria>INCLUSION CRITERIA : Newborns birth weight appropriate gestational age bear 28 , 32 , 36 40 week gestation recover common neonatal morbidity recruit enter study 5 day age . This disease condition life threaten time study . The typical disease condition expect base pilot phase study infant recover asphyxia , infant recover transient tachypnea , infant recover suspect pneumonia , infant recover hyaline membrane disease . Hyperbilirubinemia conjunction disease condition reason exclusion . Newborns birth weight tenth percentile weight distribution give gestational age bear 3034 3638 week gestation . Will include infant born 28 40 week free major neonatal morbidity recruit enter study 10 day age . EXCLUSION CRITERIA : Maternal factor may affect fatty acid metabolism neonate . Vegetarian vegan diet pregnancy Metabolic disease may affect essential fatty acid status fetus ( hyperlipidemia , diabetes ) Postnatal factor : Birth weight inadequate gestational age ( birth weight 10th percentile 90th percentile gestational age ) Significant acute neonatal morbidity interfere normal lipid metabolism study period . Infants recover common neonatal morbidity obvious effect elongase/desaturase activity exclude . Feeding prescribed study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 13, 2010</verification_date>
	<keyword>Premature Infants</keyword>
	<keyword>Fatty Acid Metabolism</keyword>
	<keyword>Polyunsaturated Fatty Acids</keyword>
	<keyword>Infant Formula</keyword>
	<keyword>Gas-chromatography</keyword>
	<keyword>Mass Spectrometry</keyword>
</DOC>